Immunotherapy for breast cancer: is it feasible?

Author:

Emens Leisha A1,Tuohy Vincent K234,Stanton Sasha E5

Affiliation:

1. Department of Oncology, Johns Hopkins University School of Medicine, Kimmel Cancer Center at Johns Hopkins

2. Department of Immunology, Cleveland Clinic, Cleveland, OH, USA

3. Department of Molecular Medicine, Lerner College of Medicine, Cleveland, OH, USA

4. Shield Biotech, Inc., Cleveland, OH, USA

5. University of Washington, Tumor Vaccine Group, Seattle, WA, USA

Abstract

Immunotherapy invited leading experts in the field to share their thoughts on two key immunotherapeutic strategies in the field of breast cancer research, vaccines and checkpoint inhibitors. Interviewed by Ellen Clarke (Commissioning Editor, Future Science Group). Historically breast cancer has been considered immunologically silent. Patients have had limited access to the types of immunotherapy available to melanoma and lung cancer patients, but this could all be set to change as recent preclinical and clinical studies have highlighted the potential of immunotherapy for breast cancer. Breast cancer is now one of the major cancer types for which new immune-based treatments are being developed.

Publisher

Future Medicine Ltd

Subject

Oncology,Immunology,Immunology and Allergy

Cited by 7 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3